Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocompatibles to return £100 million to shareholders

This article was originally published in Clinica

Executive Summary

Biocompatibles plans to give shareholders back around £100 million ($143 million) following criticism from analysts and investors about the company's planned sale of its coronary stent business to Abbott for $235 million (see Clinica No 1001, p 15). At the same time, the UK company has been named co-defendant in a lawsuit filed by US company Isostent.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065936

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel